N
Normunity
A biotechnology business that develops cutting-edge, precise immunotherapies for cancer
About Normunity
Normunity is a pioneering startup in the field of immuno-oncology, developing precision medicines that harness the power of the body's immune system to combat cancer. The company operates in the biotechnology and pharmaceutical market, serving a client base that primarily includes cancer patients who have not responded to existing immunotherapies.
Read full description
Normunity's unique approach involves the identification of previously unknown mechanisms that disrupt normal immune responses in cancer. Through their proprietary discovery engine, they uncover these points of immune disruption and target them with a new class of cancer immunotherapies, known as immune normalizers. These are designed to restore the immune system's normal function, enabling it to effectively fight cancer.
The company's business model revolves around the research, development, and commercialization of these immune normalizers. The primary source of revenue is expected to be the sale of these innovative cancer treatments once they have been approved for use.
Normunity's work is characterized by a strong partnership with the Chen lab, which provides valuable insights into the complex interactions between human cancer and the immune system. This collaboration is instrumental in the development of their groundbreaking therapies.
In summary, Normunity is a biotech startup focused on unlocking the full potential of cancer immunotherapy by developing treatments that restore the normal function of the immune system, thereby providing a new hope for cancer patients who have not responded to existing treatments.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Orange, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 50.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Normunity.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2025 | $75M | $300M | Connecticut Innovations · HongShan · Canaan · Pfizer | ↗ |
| SERIES AOther financing | Oct 2022 | $65M | $260M | Canaan · Osage University Partners · Sanofi Ventures · Taiho Ventures | ↗ |
Growth signals
Latest recorded traffic for Normunity is 2K monthly website visits, down 35.5% over the last three months. Normunity's team grew 13.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
Other known investors1 additional known investor
Yale University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Normunity on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Normunity’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.